

# John Dickson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3254186/publications.pdf>

Version: 2024-02-01

89  
papers

6,230  
citations

126858

33  
h-index

71651

76  
g-index

92  
all docs

92  
docs citations

92  
times ranked

8837  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	12.5	792
2	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1664-1675.	6.3	527
3	Functional imaging of neuroendocrine tumors with combined PET/CT using <sup>68</sup> Ga-DOTATATE (DOTA-D-Phe <sup>1</sup> , Tyr <sup>3</sup> -octreotate) and <sup>18</sup> F-FDG. <i>Cancer</i> , 2008, 112, 2447-2455.	2.0	431
4	Exenatide and the treatment of patients with Parkinson's disease. <i>Journal of Clinical Investigation</i> , 2013, 123, 2730-2736.	3.9	361
5	Attenuation Correction Synthesis for Hybrid PET-MR Scanners: Application to Brain Studies. <i>IEEE Transactions on Medical Imaging</i> , 2014, 33, 2332-2341.	5.4	311
6	Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). <i>Movement Disorders</i> , 2007, 22, 2210-2215.	2.2	304
7	A Comparison of <sup>68</sup> Ga-DOTATATE and <sup>18</sup> F-FDG PET/CT in Pulmonary Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1927-1932.	2.8	228
8	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. <i>Movement Disorders</i> , 2010, 25, 560-569.	2.2	223
9	Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 337-344.	1.5	206
10	European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 213-227.	3.3	198
11	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. <i>Lancet Neurology, The</i> , 2019, 18, 942-952.	4.9	178
12	Quantification of Myocardial Blood Flow in Absolute Terms Using <sup>82</sup> Rb PET Imaging. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1119-1127.	2.3	144
13	Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 538-545.	2.8	138
14	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1885-1912.	3.3	134
15	Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6021-6028.	3.2	123
16	The utility of <sup>18</sup> F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery. <i>Epilepsy Research</i> , 2014, 108, 1306-1314.	0.8	94
17	Diagnostic accuracy of <sup>123</sup> I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 225-229.	1.1	91
18	Does intravenous <sup>9</sup> -tetrahydrocannabinol increase dopamine release? A SPET study. <i>Journal of Psychopharmacology</i> , 2011, 25, 1462-1468.	2.0	84

#	ARTICLE	IF	CITATIONS
19	Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1529-1540.	3.3	73
20	A comparison of CT- and MR-based attenuation correction in neurological PET. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1176-1189.	3.3	70
21	The impact of reconstruction method on the quantification of DaTSCAN images. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 23-35.	3.3	67
22	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	0.8	64
23	Value of Semiquantitative Analysis for Clinical Reporting of 123I-2-Î²-Carbomethoxy-3Î²-(4-Iodophenyl)-N-(3-Fluoropropyl)Nortropine SPECT Studies. Journal of Nuclear Medicine, 2013, 54, 714-722.	2.8	62
24	Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1938-1946.	3.3	60
25	Vascular Inflammation Imaging with <sup>18</sup> F-FDG PET/CT: When to Image?. Journal of Nuclear Medicine, 2009, 50, 854-857.	2.8	59
26	Quantitative SPECT: the time is now. EJNMMI Physics, 2019, 6, 4.	1.3	56
27	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54
28	Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 188-197.	3.3	48
29	No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers. NeuroImage, 2013, 64, 61-67.	2.1	47
30	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics, 2017, 4, 8.	1.3	46
31	Oral contrast medium in PET/CT: should you or shouldn't you?. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1160-1166.	3.3	39
32	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	1.2	38
33	Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1447-1458.	3.3	35
34	Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1323-1336.	3.3	35
35	What scans we will read: imaging instrumentation trends in clinical oncology. Cancer Imaging, 2020, 20, 38.	1.2	35
36	Evaluation of a low-dose/slow-rotating SPECT-CT system. Physics in Medicine and Biology, 2008, 53, 2495-2508.	1.6	34

#	ARTICLE	IF	CITATIONS
37	18F-DOPA PET and enhanced CT imaging for congenital hyperinsulinism. Nuclear Medicine Communications, 2013, 34, 601-608.	0.5	34
38	Association of central serotonin transporter availability and body mass index in healthy Europeans. European Neuropsychopharmacology, 2014, 24, 1240-1247.	0.3	34
39	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 382-387.	1.8	34
40	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. Movement Disorders, 2012, 27, 1182-1185.	2.2	32
41	MR Imagingâ€“Guided Partial Volume Correction of PET Data in PET/MR Imaging. PET Clinics, 2016, 11, 161-177.	1.5	32
42	Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with 89Zr-oxine PET-CT. Stem Cell Research and Therapy, 2020, 11, 256.	2.4	32
43	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinsonâ€™s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The â€“Exenatide-PD3â€™ study. BMJ Open, 2021, 11, e047993.	0.8	32
44	Attenuation Correction Synthesis for Hybrid PET-MR Scanners. Lecture Notes in Computer Science, 2013, 16, 147-154.	1.0	31
45	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	3.3	29
46	Nonlaxative PET/CT Colonography: Feasibility, Acceptability, and Pilot Performance in Patients at Higher Risk of Colonic Neoplasia. Journal of Nuclear Medicine, 2010, 51, 854-861.	2.8	27
47	Dopamine reuptake transporterâ€™singleâ€™photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	2.2	25
48	Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging. Nuclear Medicine Communications, 2004, 25, 253-257.	0.5	21
49	Cardiac 82rubidium PET/CT: initial European experience. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1965-1972.	3.3	21
50	No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Research, 2013, 3, 39.	1.1	21
51	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	1.2	21
52	CT coronary angiography: Quantitative assessment of myocardial perfusion using test bolus dataâ€™initial experience. European Radiology, 2008, 18, 2155-2163.	2.3	20
53	Clinical evaluation of reducing acquisition time on single-photon emission computed tomography image quality using proprietary resolution recovery software. Nuclear Medicine Communications, 2013, 34, 1116-1123.	0.5	20
54	Novel Positron Emission Tomography/Computed Tomography of Diffuse Parenchymal Lung Disease Combining a Labeled Somatostatin Receptor Analogue and 2-Deoxy-2 [ <sup>18</sup> F] Fluoro-D-Glucose. Molecular Imaging, 2012, 11, 7290.2011.00030.	0.7	19

#	ARTICLE	IF	CITATIONS
55	Partial volume correction in SPECT reconstruction with OSEM. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2011, 648, S85-S88.	0.7	18
56	Utility of 18F-fluorodeoxyglucose positron emission tomography in presurgical evaluation of patients with epilepsy: A multicenter study. Epilepsia, 2022, 63, 1238-1252.	2.6	18
57	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	1.2	16
58	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging. EJNMMI Research, 2017, 7, 10.	1.1	16
59	Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor-Ataxia syndrome. Movement Disorders, 2009, 24, 1245-1247.	2.2	15
60	Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series. Journal of Alzheimer's Disease, 2015, 46, 639-653.	1.2	15
61	Detection and validation of the body edge in low count emission tomography images. Computer Methods and Programs in Biomedicine, 2006, 84, 153-161.	2.6	14
62	Metabolic lesion-deficit mapping of human cognition. Brain, 2020, 143, 877-890.	3.7	13
63	Associations of $\beta$ -Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. Neurology, 2022, 99, .	1.5	12
64	Does quantification have a role to play in the future of bone SPECT?. European Journal of Hybrid Imaging, 2019, 3, 8.	0.6	11
65	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. Journal of Neurology, 2013, 260, 1132-1135.	1.8	10
66	Effect of scatter correction when comparing attenuation maps: Application to brain PET/MR. , 2014, , .		10
67	Simultaneous 68Ga DOTATATE Positron Emission Tomography/Magnetic Resonance Imaging in Meningioma Target Contouring: Feasibility and Impact Upon Interobserver Variability Versus Positron Emission Tomography/Computed Tomography and Computed Tomography/Magnetic Resonance Imaging. Clinical Oncology, 2017, 29, 448-458.	0.6	10
68	Simultaneous PET/MRI in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 468-469.	3.3	9
69	A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1032-1034.	0.9	9
70	Quantitative SPECT. Nuclear Medicine Communications, 2019, 40, 986-994.	0.5	9
71	Assessment of left ventricular function at rest using rubidium-82 myocardial perfusion PET: comparison of four software algorithms with simultaneous 64-slice coronary CT angiography. Nuclear Medicine Communications, 2009, 30, 918-925.	0.5	7
72	PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1591-1594.	3.3	7

#	ARTICLE	IF	CITATIONS
73	Underestimation of <sup>68</sup> Ga PET/CT SUV caused by activity overestimation using default calibrator settings. <i>Physica Medica</i> , 2019, 59, 158-162.	0.4	7
74	The effect of modern PET technology and techniques on the EANM paediatric dosage card. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1964-1969.	3.3	7
75	Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. <i>Diagnostics</i> , 2021, 11, 2333.	1.3	7
76	Comparison of rubidium-82 myocardial blood flow quantification with coronary calcium score for evaluation of coronary artery stenosis. <i>Nuclear Medicine Communications</i> , 2016, 37, 197-206.	0.5	5
77	An assessment of perfusion deficits in decompression illness using <sup>99</sup> Tcm HMPAO SPET and statistical parametric mapping. <i>Nuclear Medicine Communications</i> , 2001, 22, 423-428.	0.5	3
78	Evaluation of an OSEM-based PVC method for SPECT with clinical data. , 2010, , .		2
79	P1-286: STRATIFICATION OF DEMENTIA SUB-TYPES USING ARTERIAL SPIN LABELED MRI. , 2014, 10, P414-P415.		1
80	Establishment of an open database of realistic simulated data for evaluation of partial volume correction techniques in brain PET/MR. <i>EJNMMI Physics</i> , 2015, 2, A44.	1.3	1
81	<sup>18</sup> F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies. <i>American Journal of Roentgenology</i> , 2016, 207, 1297-1306.	1.0	1
82	101 poster: Techniques to Delineate Hypoxic BTV Using <sup>64</sup> CU-ATSM in Squamous Cell Carcinoma of the Head and Neck. <i>Radiotherapy and Oncology</i> , 2010, 94, S39-S40.	0.3	0
83	86 poster: Advantages of Fixed and Adaptive <sup>18</sup> F-FDG PET/CT Based BTV Delineation in Squamous Cell Carcinoma of the Head and Neck : Effect on Dose Escalated IMRT.. <i>Radiotherapy and Oncology</i> , 2010, 94, S33-S34.	0.3	0
84	USING FLORBETAPIR PET TO INCREASE DIAGNOSTIC CERTAINTY IN ATYPICAL DEMENTIAS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.112-e4.	0.9	0
85	[ICâ€Pâ€004]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2017, 13, P12.	0.4	0
86	[P3â€348]: EXPLORING THE POPULATION PREVALENCE OF Î²â€AMYLOID BURDEN: AN ANALYSIS OF 250 INDIVIDUALS BORN IN MAINLAND BRITAIN IN THE SAME WEEK IN 1946. <i>Alzheimer's and Dementia</i> , 2017, 13, P1088.	0.4	0
87	[P3â€373]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2017, 13, P1100.	0.4	0
88	Vascular risk factors and amyloid pathology: Additive or interactive associations?. <i>Alzheimer's and Dementia</i> , 2020, 16, e037922.	0.4	0
89	Hybrid Imaging in conventional nuclear medicine. , 2020, , .		0